The Eczacıbaşı Group to acquire Gensenta from Amgen for $135m.

The Eczacıbaşı Group, a Turkish industrial group, agreed to acquire Gensenta, a manufacturer of pharmaceutical products, from Amgen, a biotechnology-based human therapeutics services, for $135m. “As a company that aspires to being a pioneer of modern, high quality and healthy living, we will expand our healthcare activities both in Turkey and international markets with innovative products and a wide product portfolio in different treatment areas. This acquisition fuels our growth by adding local production capabilities in pharmaceuticals, biosimilar products, and active ingredients to our investment portfolio as well as export competency," Bülent Eczacıbaşı, Eczacıbaşı Chairperson.